IVXA-12 is under clinical development by Icosavax and currently in Phase II for Respiratory Syncytial Virus (RSV) Infections. According to GlobalData, Phase II drugs for Respiratory Syncytial Virus (RSV) Infections does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the IVXA-12 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IVXA-12 is under development for the prevention of human metapneumovirus (hMPV) and respiratory syncytial virus (RSV) infections. It is a bivalent vaccine and is being developed based on virus-like article (VLP) technology. It is administered through intramuscular route.
Icosavax is a biotechnology company that develops vaccines for infectious diseases such as respiratory syncytial virus. The company is headquartered in Seattle, Washington, the US.
For a complete picture of IVXA-12’s drug-specific PTSR and LoA scores, buy the report here.